Synovial and serum levels of NGF in osteoarthritis and rheumatic diseases: a systematic review

M. Baldini, L. Farinelli, P. Luciani, S. Manzotti, F. Salaffi, A. Gigante

Article ID: 5579
Vol 34, Issue 5S1, 2020
DOI: https://doi.org/10.54517/jbrha5579
Received: 8 November 2020; Accepted: 8 November 2020; Available online: 8 November 2020; Issue release: 8 November 2020

Abstract

NGF has raised interest as a target molecule in the treatment of OA, after the clinical evidences that antagonization of NGF axis provides symptoms relief in OA. Thus, we conducted a systematic review of the literature to investigate the evidence of NGF being overexpressed during OA. We conducted a database search on Medline using keywords including NGF, serum, synovial fluid, AND osteoarthritis or arthritis. We included study conducted on human, with serum or synovial specimens and an OA cohort. Nine studies met the inclusion criteria. Serum levels ranged from non-detectable to 153.5±28.6 pg/ml. Synovial fluid levels ranged from non-detectable to nearly 210±82 pg/ml. One study supported the evidence of an increased level of NGF in SF and serum of OA patients. The concentration of NGF reported in these studies is controversial and evidence of overexpression of NGF is low


Keywords

NGF;Osteoarthritis;serum levels;synovial fluid


References

Supporting Agencies



Copyright (c) 2020 M. Baldini, L. Farinelli, P. Luciani, S. Manzotti, F. Salaffi, A. Gigante




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).